Biomarker testing could dramatically improve patient health outcomes.
Scientific innovations like gene editing, AI and robotic surgery have revolutionised the ways we find, understand and treat disease. One precision technology in particular — biomarker testing — is helping doctors and patients identify the treatment plans most likely to work for them.
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology.